The Subsidiaries of Hengrui Pharma Gained Clinical Trial Approval Again

Healthcare Author: Mianmian Wang May 19, 2022 12:28 PM (GMT+8)

It will further complete the pipeline drug profiles of the pharma giant, Hengrui Pharma.

Hengrui medicine

Jiangsu Hengrui Pharma released a document last night that Guangdong Hengrui Pharma (Chinese: 广东恒瑞医药) and Suzhou Suncadia Biopharma (Chinese: 苏州盛迪亚生物医药), the subsidiaries of Hengrui Pharma are granted the approval of clinicl trial for SHR-2010 injection by National medical products administration (NMPA). The clinical trial will be started soon.  

According to Hengrui Pharma, SHR-2010 can improve the glomerulonephritis caused by the thickened glomerular basement membrane (GBM) thereby to treat IgA nephtopathy (Berger’s disease). Hengrui Pharma has invested approximately CNY 24.56 million (USD 3.6 million) in the R&D of SHR-2010. 

So far, there have not been any drugs in this category in both domestic and overseas market yet.